课题基金 / 基金详情

Oncolytic viral therapy for disseminated peritoneal ovarian cancer using a novel replication-competent herpes simplex virus type 1 mutant in mice.

Oncolytic viral therapy for disseminated peritoneal ovarian cancer using a novel replication-competent herpes simplex virus type 1 mutant in mice.
使用新型具有复制能力的 1 型单纯疱疹病毒突变体对小鼠进行溶瘤病毒治疗,用于治疗播散性腹膜卵巢癌。
批准号:
13671760
负责人:
NAWA Akihiro
金额:
$2.37万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

NAWA Akihiro的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We prepared two attenuated mutant HSV-1 strains. One is an HSV-1 mutant, hrR3, and another is a new replication competent HSV-1 mutant, HR522 ; this virus, expressing the lacZ reporter gene, induces syncytium formation in infected cells. We compared the efficacy of HR522 with Taxol and hrR3 in the treatment of nude mice harboring human ovarian cancer cells. We also examined the effect of the prodrug ganciclovir (GCV) on the treatment mediated by these HSVs. The survival of mice treated with a high titer hrR3 (5x10^7 plaque-forming units ; PFU) was significantly prolonged as compared to the group given Taxol (p<0.0001 ; Log-Rank test). Although the survival of mice treated with high titer HR522 (5x10^7 PFU) was not significantly prolonged compared with Taxol-treated group (p=0.212 ; Log-Rank test), GCV markedly enhanced the efficacy of HR522 administration (p<0.005 ; vs Taxol ; Log-Rank test). The lacZ gene product, visualized using 5-brorno-4-chrolo-3-indoryl-β-D- galactopyranoside (X-gal) histochemistry, was detected in HR522-treated tumors in areas also exhibiting apoptotic changes. Another study demonstrated that a clonal derivative of HSV-1 strain HF done 10 very effectively treated peritoneally disseminated neoplasm in an immunocompetent animal model and that all of survived mice acquired resistance to rechallenge of tumor cells. HF clone 10 induces syncytia formation in vitro. A sequential administration ofHF clone 10 attained a long-term survival over 90 days after tumor injection in 8 of the 9 treated mice without any signs of diseases. The results suggested that treatment of peritoneally disseminated tumor with HF clone 10 induced a specific anti-tumor immune response. We found that clone 10 has a deletion of 39kbp in the right end of UL and UL/IRL junction, resulting in the loss of UL 56 expression. Moreover, a 23kbp deletion and extensive rearrangement were observed in the left end of the genome.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Nicolson GL, Nawa A, et al.: "Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation"Clinical experimental metastasis. (in press).
Nicolson GL、Nawa A等人:“肿瘤转移相关的人MTA1基因及其MTA1蛋白产物:在上皮癌细胞侵袭、增殖和核调节中的作用”临床实验转移。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takakuwa H, Nawa A, Nishiyama Y, et al.: "Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for peritoneally disseminated tumor in immunocompetent mice"Archives of Virology. (in press).
Takakuwa H、Nawa A、Nishiyama Y 等人:“使用自发产生的单纯疱疹病毒 1 型变体进行溶瘤病毒疗法,用于免疫活性小鼠的腹膜播散性肿瘤”病毒学档案。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Establishment of polymer-equipped oncolytic virotherapeutics against ovarian cancer.
The development of the new cancer virus, cell therapy for ovarian cancer and the analysis of immune system response
Development of a novel oncolytic virotherapy for ovarian cancer and primary peritoneal serous carcinoma
  • 批准号:
    19591930
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.83万
  • 财政年份:
    2007
  • 负责人:
    NAWA Akihiro
  • 依托单位:
The development of a novel genetherapy for pelitoneal dissemination of ovarian cancer using HSV-1 and its amplicon system.